Treatment of hypercalcaemia of malignancy in adults.
antiresorptive
bisphosphonate
calcimimetic
calcitonin
cancer
denosumab
glucocorticoids
hypercalcaemia
malignancy
parathyroid cancer
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
medline:
4
10
2023
pubmed:
30
9
2023
entrez:
29
9
2023
Statut:
ppublish
Résumé
Hypercalcaemia of malignancy (HCM) is a common metabolic complication of advanced malignancies with a prevalence varying from 2-30%, depending on cancer type and disease stage. HCM is associated with impaired quality of life, increased risk of hospitalisation and limited survival. Evidence-based guidelines for management of HCM have been lacking to date, despite its prevalence and detrimental impact. This concise guidance highlights key recommendations from the recent Endocrine Society Clinical Practice Guidelines on Treatment of Hypercalcaemia of Malignancy in Adults, published in December 2022. A systematic review and meta-analysis was commissioned to support the guideline development process. Key suggestions include the use of denosumab in preference to intravenous bisphosphonates as first-line treatment for HCM and the use of denosumab in cases of recurrent or refractory HCM in patients previously treated with intravenous bisphosphonates. The guideline also identifies priority areas for future research.
Identifiants
pubmed: 37775175
pii: 23/5/503
doi: 10.7861/clinmed.2023-0227
pmc: PMC10541286
doi:
Substances chimiques
Denosumab
4EQZ6YO2HI
Diphosphonates
0
Bone Density Conservation Agents
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-507Informations de copyright
© Royal College of Physicians 2023. All rights reserved.
Références
J Clin Endocrinol Metab. 2015 May;100(5):2024-9
pubmed: 25719931
J Clin Oncol. 2001 Jan 15;19(2):558-67
pubmed: 11208851
J Clin Oncol. 2010 Dec 10;28(35):5132-9
pubmed: 21060033
Am J Nephrol. 2015;41(2):129-37
pubmed: 25790847
J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8
pubmed: 17666472
J Clin Endocrinol Metab. 2012 Apr;97(4):1153-8
pubmed: 22442274
Gac Sanit. 2018 Mar - Apr;32(2):167.e1-167.e10
pubmed: 28917831
Endocrinol Metab Clin North Am. 2021 Dec;50(4):721-728
pubmed: 34774243
Lancet Oncol. 2018 Mar;19(3):370-381
pubmed: 29429912
J Clin Endocrinol Metab. 2023 Feb 15;108(3):507-528
pubmed: 36545746
Calcif Tissue Int. 1990;46 Suppl:S26-30
pubmed: 2137363
N Engl J Med. 2022 Apr 14;386(15):1443-1451
pubmed: 35417639
J Clin Endocrinol Metab. 2013 Oct;98(10):4023-9
pubmed: 23979953
Eur J Cancer. 2015 Jul;51(11):1467-75
pubmed: 25976743
J Adv Pract Oncol. 2018 Jul-Aug;9(5):496-504
pubmed: 31086686
Endocr Connect. 2016 Sep;5(5):G9-G11
pubmed: 27935816
J Clin Endocrinol Metab. 2023 Feb 15;108(3):585-591
pubmed: 36545700
Arch Intern Med. 2012 Jun 25;172(12):930-6
pubmed: 22732749